NASDAQ:VVOS

Vivos Therapeutics Stock Insider Trading

etoro logo Buy VVOS
*Your capital is at risk
$0.643
-0.0351 (-5.18%)
At Close: Jun 03, 2026

Vivos Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 26.22M and sold 0 VVOS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
100.00
Buy 26.22M shares
Sell 0 shares
100% Buy Activity
Negligible or No Correlation

No Significant Signals

No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date Type Person Role Amount
Dec 23, 2022
Buy
Stock Option (Right to Buy)
A-Award
Thompson Matthew
Director
Director 30 000
Value: $14.4K
Dec 23, 2022
Buy
Stock Option (Right to Buy)
A-Award
Huntsman Ronald Kirk
Chief Executive Officer
CEO / President 150 000
Value: $72.0K
Dec 23, 2022
Buy
Stock Option (Right to Buy)
A-Award
Huntsman Ronald Kirk
Chief Executive Officer
CEO / President 333 334
Value: $160.0K
Dec 23, 2022
Buy
Common Stock
P-Purchase
Huntsman Ronald Kirk
Chief Executive Officer
CEO / President 20 000
Value: $10.0K
Dec 23, 2022
Buy
Stock Option (Right to Buy)
A-Award
Lindsay Mark F.
Director
Director 30 000
Value: $14.4K
Dec 23, 2022
Buy
Stock Option (Right to Buy)
A-Award
Amman Bradford K.
Chief Financial Officer
C-Suite Officer 200 000
Value: $96.0K
Dec 23, 2022
Buy
Stock Option (Right to Buy)
A-Award
Green Ralph Elias
Director
Director 30 000
Value: $14.4K
Dec 23, 2022
Buy
Stock Option (Right to Buy)
A-Award
Krammer Anja B
Director
Director 30 000
Value: $14.4K
Dec 23, 2022
Buy
Stock Option (Right to Buy)
A-Award
Sokolow Leonard J
Director
Director 30 000
Value: $14.4K
Dec 23, 2022
Buy
Stock Option (Right to Buy)
A-Award
Thompson Matthew
Director
Director 30 000
Value: $14.4K
Dec 23, 2022
Buy
Stock Option (Right to Buy)
A-Award
Huntsman Ronald Kirk
Chief Executive Officer
CEO / President 150 000
Value: $72.0K
Dec 23, 2022
Buy
Stock Option (Right to Buy)
A-Award
Huntsman Ronald Kirk
Chief Executive Officer
CEO / President 333 334
Value: $160.0K
Dec 23, 2022
Buy
Common Stock
P-Purchase
Huntsman Ronald Kirk
Chief Executive Officer
CEO / President 20 000
Value: $10.0K
Dec 23, 2022
Buy
Stock Option (Right to Buy)
A-Award
Lindsay Mark F.
Director
Director 30 000
Value: $14.4K
Dec 23, 2022
Buy
Stock Option (Right to Buy)
A-Award
Amman Bradford K.
Chief Financial Officer
C-Suite Officer 200 000
Value: $96.0K
Dec 23, 2022
Buy
Stock Option (Right to Buy)
A-Award
Green Ralph Elias
Director
Director 30 000
Value: $14.4K
May 31, 2022
Buy
Common Stock
P-Purchase
Huntsman Ronald Kirk
Chief Executive Officer
CEO / President 8 000
Value: $16.2K
May 31, 2022
Buy
Common Stock
P-Purchase
Huntsman Ronald Kirk
Chief Executive Officer
CEO / President 8 000
Value: $16.2K
Feb 25, 2022
Buy
Stock Option (Right to Buy)
A-Award
Huntsman Ronald Kirk
Chief Executive Officer
CEO / President 125 000
Value: $408.8K
Feb 25, 2022
Buy
Stock Option (Right to Buy)
A-Award
Amman Bradford K.
Chief Financial Officer
C-Suite Officer 50 000
Value: $163.5K
Feb 25, 2022
Buy
Stock Option (Right to Buy)
A-Award
Huntsman Ronald Kirk
Chief Executive Officer
CEO / President 125 000
Value: $408.8K
Feb 25, 2022
Buy
Stock Option (Right to Buy)
A-Award
Amman Bradford K.
Chief Financial Officer
C-Suite Officer 50 000
Value: $163.5K
Sep 21, 2021
Buy
Common Stock
P-Purchase
Huntsman Ronald Kirk
Chief Executive Officer
CEO / President 5 000
Value: $21.6K
Sep 21, 2021
Buy
Common Stock
P-Purchase
Huntsman Ronald Kirk
Chief Executive Officer
CEO / President 5 000
Value: $21.6K
Aug 31, 2021
Buy
Stock Option (Right to Buy)
A-Award
Amman Bradford K.
Chief Financial Officer
C-Suite Officer 50 000
Value: $263.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT VIVOS THERAPEUTICS, INC.
Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening ...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE